Clinical development of voruciclib to be advanced and new formulation of ME-344 to be enabled April 16, 2024
FDA Clearance To Initiate Ph 1/2 Clinical with TTX-MC138 in Advanced Solid Tumors Announced April 16, 2024
Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors April 9, 2024
CytomX Therapeutics Announces Nomination of Second Clinical Candidate in Broad PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas April 9, 2024
Enhertu approved in the US as first tumour-agnostic HER2-directed therapy for previously treated patients with metastatic HER2-positive solid tumours April 8, 2024
Gilead And Xilio Announce Exclusive License Agreement For Tumor-Activated IL-12 Program April 2, 2024
Edgewood Oncology raises $20 Million in Series A Financing to Advance BTX-A51 in Patients with Hematologic Malignancies and Genetically-Defined Solid Tumors April 2, 2024
First Patient Dosed in Ph 1/2a Trial of IMM-6-415 in Advanced Solid Tumors with RAF/RAS Mutations April 2, 2024
First Patient Dosed in Tumor-Agnostic Ph 2 PYNNACLE Trial for Rezatapopt in TP53 Y220C+ve Solid Tumors April 2, 2024
ARYA-3 Clinical Trial Advances to Ph 2 for Treatment of Liver Cancer Using GPC3-Targeting ARTEMIS T-cell Therapy March 26, 2024
Positive Topline Results Announced from Ph 1 Portion of Ph 1/2a Trial of IMM-1-104 in RAS-Mutant Solid Tumors March 26, 2024
Tubulis Closes Upsized €128 Million Series B2 to Accelerate Clinical Development of Solid Tumor-Focused ADC Pipeline March 18, 2024
Domain Therapeutics and Chime Biologics announce manufacturing agreement to advance novel anti-CCR8 antibody for cancer immunotherapy March 18, 2024
Biotheus Expanded Partnership with Hansoh Pharma for Developing EGFR/cMET Bispecific ADCs March 18, 2024
Debio0123 Monotherapy trial expanded In Gynecological Cancers And Other Biomarker-Driven Solid Tumors March 12, 2024
Positive Interim Data of Dose Escalation Phase of ALG.APV-527 Ph 1 Study in Solid Tumor Cancers Expressing Tumor Antigen 5T4 announced March 12, 2024
Vudalimab monotherapy generally well tolerated with encouraging clinical benefit for heavily-pretreated patients with high-risk metastatic CRPC March 5, 2024
Encouraging Safety & Efficacy Data in Dose Escalation Trials for PSMAxCD3-TRACTr JANX007 in metastatic CRPC and EGFRxCD3-TRACTr JANX008 in Solid Tumors Announced March 5, 2024
Enhertu granted Priority Review in the US for patients with metastatic HER2-positive solid tumours February 26, 2024
